Sustained activation of the JAK-STAT signaling pathway is a key driver in the initiation and progression of T-cell acute lymphoblastic leukemia (T-ALL), with activating mutations in JAK1 (e.g., V658F) and JAK3 (e.g., M511I) commonly reported in T-ALL cases. This evidence concerns the gene JAK3 and acute lymphoblastic leukemia.